MiR-21 and Tocilizumab interactions improve COVID-19 myocarditis outcomes

Background: Myocarditis is now one of the most fatal and morbid complications of COVID-19. Many scientists have recently concentrated on this problem. Objectives: This study assessed the effects of Remdesivir (RMS) and Tocilizumab (TCZ) in COVID-19 myocarditis. Design: Observational, cohort study. M...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in cardiovascular disease 2023-01, Vol.17, p.17539447231182548-17539447231182548
Main Authors: Hossein Heydari, Amir, Ghaffari, Saeid, Khani, Zahra, Heydari, Sophia, Eskandari, Zakaria, Esmaeil Heidari, Mohammad
Format: Article
Language:English
Subjects:
Antiviral drugs
Cardiac function
Cohort Studies
COVID-19
COVID-19 Drug Treatment
Humans
MicroRNAs
Monoclonal antibodies
Mortality
Myocarditis
Myocarditis - drug therapy
Original Research
Retrospective Studies
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Myocarditis is now one of the most fatal and morbid complications of COVID-19. Many scientists have recently concentrated on this problem. Objectives: This study assessed the effects of Remdesivir (RMS) and Tocilizumab (TCZ) in COVID-19 myocarditis. Design: Observational, cohort study. Methods: Patients with COVID-19 myocarditis were enrolled in the study and divided into three groups, TCZ-treated, RMS-treated, and Dexamethasone-treated patients. After 7 days of treatment, patients were reassessed for improvement. Results: TCZ significantly improved patients’ ejection fraction in 7 days, but it had limited efficacy. RMS improved inflammatory characteristics of the disease, but RMS-treated patients showed exacerbated cardiac function over 7 days, and the mortality rate with RMS was higher than TCZ. TCZ protects the heart by decreasing the miR-21 expression rate. Conclusion: Using Tocilizumab in early diagnosed COVID-19 myocarditis patients can save their cardiac function after hospitalization and decrease the mortality rate. miR-21 level determines the outcome and responsiveness of COVID-19 myocarditis to treatment.
ISSN:1753-9447
1753-9455
DOI:10.1177/17539447231182548